Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 749 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs January 27, 2022 What could DeepMind ‘solving’ the protein folding problem mean for cancer... December 23, 2020 A Pet Pug Helped Two Sisters Realize They Both Had Breast... October 16, 2020 Air Pollution and Breast Cancer Risk – A Link That Calls... October 17, 2023 Load more HOT NEWS This Harmful Chemical Is Still Being Used In Popular Household Products 21-Month-Old Girl Celebrates After Beating Stage 4 Cancer Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban Talazoparib Plus Enzalutamide Improves rPFS in First-Line Treatment for Patients with...
